Syntax Bio provides a discovery platform that uses its proprietary Cellgorithm technology to directly control and accelerate stem cell differentiation, mimicking human developmental cues to produce a wide variety of functional cell types. The platform shortens development timelines, lowers costs, and offers scalable, reproducible workflows that act as a force multiplier for large biopharma and cell therapy programs, enabling faster preclinical and clinical translation of therapies such as pancreatic beta cells for type 1 diabetes.
Funding
$33.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing stem cell-derived therapies is hindered by slow, costly, and inefficient cell differentiation processes, making it difficult to generate the diverse, functional cell types needed for clinical programs and limiting patient access.
Solution
Syntax Bio offers a discovery platform that directly controls and accelerates stem cell differentiation using its proprietary Cellgorithm technology, which emulates human developmental pathways to produce a broad spectrum of functional cell types. The platform shortens development timelines and reduces costs, acting as a force multiplier for existing cell therapy programs. By providing scalable, reproducible differentiation workflows, Syntax enables biopharma partners to explore new product opportunities and advance therapies such as pancreatic beta cells for type 1 diabetes.
Target Audience
Primary customers are large biopharma organizations and cell therapy developers seeking to accelerate and de‑risk their stem cell‑derived product pipelines.
Features
- Cellgorithm proprietary technology that mimics human developmental cues to drive rapid, directed differentiation
- Generation of a wide diversity of functional cell types from a single stem cell source
- Integrated workflow that reduces discovery time and lowers manufacturing costs
- Scalable platform compatible with existing cell therapy pipelines, facilitating faster preclinical and clinical translation
- Data-driven optimization tools that improve reproducibility and predictability of cell product quality